Cancer Cachexia Market Research and Forecast 2024-2033: Key Growth Segments and Trends

Global cancer cachexia market size is expected to reach $3.14 Bn by 2028 at a rate of 6.2%, segmented as by therapeutics, progestogens, corticosteroids, combination therapies, other therapeutics

Jun 27, 2024 - 15:41

0 9

Cancer Cachexia Market Research and Forecast 2024-2033: Key Growth Segments and Trends

Overview and Scope
Cancer cachexia is a complex metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, fatigue, and loss of appetite in individuals with cancer. It is a multifactorial condition resulting from a combination of factors such as inflammation, metabolic abnormalities, and the presence of tumors. Cancer cachexia can significantly impact a patient's quality of life, impairing their ability to tolerate cancer treatments and reducing their overall survival.

Sizing and Forecast
The cancer cachexia market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $ 2.47 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to an improved understanding of cancer biology, the prevalence of cancer, an increased aging population, a greater focus on patient-centered care, expanding treatment options, and growing awareness among healthcare providers.

The cancer cachexia market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising awareness about cachexia management, expanding geriatric population, growing adoption of novel therapeutic approaches, rising healthcare expenditure, and favorable government initiatives. Major trends in the forecast period include increasing research and development efforts, expanding therapeutic options, improved diagnosis rates, adoption of novel treatment modalities, and advancements in supportive care strategies.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Segmentation & Regional Insights
The cancer cachexia market covered in this report is segmented –

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics
2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions
3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of cancer is expected to propel the growth of the cancer cachexia market going forward. Cancer refers to a condition where abnormal cells proliferate uncontrollably in the body, forming tumors and disrupting normal bodily processes. The cases of cancer is attributed to various factors, including lifestyle changes, environmental factors, an aging population, genetic predisposition, improved diagnostic methods leading to earlier detection, and increased awareness, prompting more people to seek medical attention. Advancements in medical technology and a greater understanding of cancer and its complications are resulting in more frequent diagnoses and reporting of cancer cachexia. Healthcare professionals are improving their ability to identify cachexia symptoms, facilitating earlier interventions and treatment commencement. For instance, in December 2023, according to the Australian Bureau of Statistics, an Australia-based government agency for national statistics, roughly 1.8% of the population, or 456,200 individuals, were reported to have cancer in Australia in 2022. Furthermore, in December 2021, according to the Australian Institute of Health and Welfare, an Australia-based government agency for health and welfare, approximately 151,000 Australians received a cancer diagnosis, equating to around 413 diagnoses per day in 2021. Therefore, the increasing prevalence of cancer is driving the growth of the cancer cachexia market.

Key Industry Players
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

The cancer cachexia market report table of contents includes:

1. Executive Summary
2. Cancer Cachexia Market Characteristics
3. Cancer Cachexia Market Trends And Strategies
4. Cancer Cachexia Market - Macro Economic Scenario
5. Global Cancer Cachexia Market Size and Growth
.
.
.
31. Global Cancer Cachexia Market Competitive Benchmarking
32. Global Cancer Cachexia Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Cancer Cachexia Market
34. Cancer Cachexia Market Future Outlook and Potential Analysis
35. Appendix